Charlotte J. Imianowski

Charlotte J. Imianowski

Auto-generated profile, based on publicly available information

Charlotte J. Imianowski

Department of Pathology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
CICharlotte J. Imianowski
Charlotte J. Imianowski
QCQiang Chen
Qiang Chen
CWCreg J. Workman
Creg J. Workman
DVDario A. A. Vignali
Dario A. A. Vignali

5 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
JYJie Yang
Jie Yang
YYYumi Yamashita-Kanemaru
Yumi Yamashita-Kanemaru
BMBenjamin I. Morris
Benjamin I. Morris
ACAnnalisa Contursi
Annalisa Contursi
DTDaniel Trajkovski
Daniel Trajkovski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Metastasis is the spread of cancer cells from primary tumours to distant organs and is the cause of 90% of cancer deaths globally1,2. Metastasizing cancer cells are uniquely vulnerable to immune attack, as they are initially deprived of the immunosuppressive microenvironment found within established tumours3. There is interest in therapeutically exploiting this immune vulnerability to prevent recurrence in patients with early cancer at risk of metastasis. Here we show that inhibitors of cyclooxygenase 1 (COX-1), including aspirin, enhance immunity to cancer metastasis by releasing T cells from suppression by platelet-derived thromboxane A2 (TXA2). TXA2 acts on T cells to trigger an immunosuppressive pathway that is dependent on the guanine exchange factor ARHGEF1, suppressing T cell receptor-driven kinase signalling, proliferation and effector functions. T cell-specific conditional deletion of Arhgef1 in mice increases T cell activation at the metastatic site, provoking immune-mediated rejection of lung and liver metastases. Consequently, restricting the availability of TXA2 using aspirin, selective COX-1 inhibitors or platelet-specific deletion of COX-1 reduces the rate of metastasis in a manner that is dependent on T cell-intrinsic expression of ARHGEF1 and signalling by TXA2 in vivo. These findings reveal a novel immunosuppressive pathway that limits T cell immunity to cancer metastasis, providing mechanistic insights into the anti-metastatic activity of aspirin and paving the way for more effective anti-metastatic immunotherapies.

10 February 2025 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
PSPuspendu Sardar
Puspendu Sardar
BBBenjamin S. Beresford-Jones
Benjamin S. Beresford-Jones
WXWangmingyu Xia
Wangmingyu Xia
OSOmar Shabana
Omar Shabana
SSSatoshi Suyama
Satoshi Suyama
VPVirginia A. Pedicord
Virginia A. Pedicord
The gut microbiome modulates immunotherapy treatment responses, and this may explain why immune checkpoint inhibitors, such as anti-PD-1, are only effective in some patients. Previous studies correlated lipopolysaccharide (LPS)-producing gut microbes with poorer prognosis; however, LPS from diverse bacterial species can range from immunostimulatory to inhibitory. Here, by functionally analysing faecal metagenomes from 112 patients with melanoma, we found that a subset of LPS-producing bacteria encoding immunostimulatory hexa-acylated LPS was enriched in microbiomes of clinical responders. In an implanted tumour mouse model of anti-PD-1 treatment, microbiota-derived hexa-acylated LPS was required for effective anti-tumour immune responses, and LPS-binding antibiotics and a small-molecule TLR4 antagonist abolished anti-PD-1 efficacy. Conversely, oral administration of hexa-acylated LPS to mice significantly augmented anti-PD-1-mediated anti-tumour immunity. Penta-acylated LPS did not improve anti-PD-1 efficacy in vivo and inhibited hexa-acylated LPS-induced immune activation in vitro. Microbiome hexa-acylated LPS therefore represents an accessible predictor and potential enhancer of immunotherapy responses.

15 December 2023 in Science Immunology
Verified
Journal Article
Open access
SWSarah K. Whiteside
Sarah K. Whiteside
FGFrancis M. Grant
Francis M. Grant
GAGiorgia Alvisi
Giorgia Alvisi
JCJames Clarke
James Clarke
LTLeqi Tang
Leqi Tang
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T (T reg ) cells contribute to immune homeostasis but suppress immune responses to cancer. Strategies to disrupt T reg cell–mediated cancer immunosuppression have been met with limited clinical success, but the underlying mechanisms for treatment failure are poorly understood. By modeling T reg cell–targeted immunotherapy in mice, we find that CD4 + Foxp3 − conventional T (T conv ) cells acquire suppressive function upon depletion of Foxp3 + T reg cells, limiting therapeutic efficacy. Foxp3 − T conv cells within tumors adopt a T reg cell–like transcriptional profile upon ablation of T reg cells and acquire the ability to suppress T cell activation and proliferation ex vivo. Suppressive activity is enriched among CD4 + T conv cells marked by expression of C-C motif receptor 8 (CCR8), which are found in mouse and human tumors. Upon T reg cell depletion, CCR8 + T conv cells undergo systemic and intratumoral activation and expansion, and mediate IL-10–dependent suppression of antitumor immunity. Consequently, conditional deletion of Il10 within T cells augments antitumor immunity upon T reg cell depletion in mice, and antibody blockade of IL-10 signaling synergizes with T reg cell depletion to overcome treatment resistance. These findings reveal a secondary layer of immunosuppression by T conv cells released upon therapeutic T reg cell depletion and suggest that broader consideration of suppressive function within the T cell lineage is required for development of effective T reg cell–targeted therapies.

30 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CICharlotte J. Imianowski
Charlotte J. Imianowski
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa Lozano
Teresa Lozano
AEAlexander C. Evans
Alexander C. Evans
JBJayme D. Benson
Jayme D. Benson
RRRahul Roychoudhuri
Rahul Roychoudhuri
Natural killer (NK) cells are critical to immune surveillance against infections and cancer. Their role in immune surveillance requires that NK cells are present within tissues in a quiescent state. Mechanisms by which NK cells remain quiescent in tissues are incompletely elucidated. The transcriptional repressor BACH2 plays a critical role within the adaptive immune system, but its function within innate lymphocytes has been unclear. Here, we show that BACH2 acts as an intrinsic negative regulator of NK cell maturation and function. BACH2 is expressed within developing and mature NK cells and promotes the maintenance of immature NK cells by restricting their maturation in the presence of weak stimulatory signals. Loss of BACH2 within NK cells results in accumulation of activated NK cells with unrestrained cytotoxic function within tissues, which mediate augmented immune surveillance to pulmonary cancer metastasis. These findings establish a critical function of BACH2 as a global negative regulator of innate cytotoxic function and tumor immune surveillance by NK cells.

26 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
QZQiuchen Zhao
Qiuchen Zhao
JPJhuma Pramanik
Jhuma Pramanik
YLYongjin Lu
Yongjin Lu
NHNatalie Zingra Mary Homer
Natalie Zingra Mary Homer
CICharlotte J. Imianowski
Charlotte J. Imianowski
BMBidesh Mahata
Bidesh Mahata
Breast cancer, particularly triple-negative breast cancer (TNBC), evades the body’s immune defences, in part by cultivating an immunosuppressive tumour microenvironment. Here, we show that suppressing local steroidogenesis can augment anti-tumour immunity against TNBC. Through targeted metabolomics of steroids coupled with immunohistochemistry, we profiled the existence of immunosuppressive steroids in TNBC patient tumours and discerned the steroidogenic activity in immune-infiltrating regions. In mouse, genetic inhibition of immune cell steroidogenesis restricted TNBC tumour progression with a significant reduction in immunosuppressive components such as tumour associated macrophages. Steroidogenesis inhibition appears to bolster anti-tumour immune responses in dendritic and T cells by impeding glucocorticoid signalling. Undertaking metabolic modelling of the single-cell transcriptomics and targeted tumour-steroidomics, we pinpointed the predominant steroidogenic cells. Inhibiting steroidogenesis pharmacologically using a identified drug, posaconazole, curtailed tumour expansion in a humanised TNBC mouse model. This investigation paves the way for targeting steroidogenesis and its signalling pathways in breast cancer affected by immune-steroid maladaptation.